Advancements in Urothelial Cancer Care: Optimizing Treatment for Your Patient

Gregory Hemenway, Jonathan F Anker, Paul Riviere, Brent S Rose, Matthew D Galsky, Pooja Ghatalia

Research output: Contribution to journalReview articlepeer-review


The standard treatment paradigm for muscle invasive bladder cancer has been neoadjuvant cisplatin-based chemotherapy followed by radical cystectomy. However, efforts are ongoing to personalize treatment by incorporating biomarkers to better guide treatment selection. In addition, bladder preservation strategies are aimed at avoiding cystectomy in well-selected patients. Similarly, in the metastatic urothelial cancer space, the standard frontline treatment option of platinum-based chemotherapy has changed with the availability of data from EV-302 trial, making the combination of enfortumab vedotin (EV) and pembrolizumab the preferred first-line treatment option. Here, we examine the optimization of treatment intensity and sequencing, focusing on the challenges and opportunities associated with EV/pembrolizumab therapy, including managing toxicities and exploring alternative dosing approaches. Together, these articles provide a comprehensive overview of contemporary strategies in bladder cancer management, highlighting the importance of individualized treatment approaches, ongoing research, and multidisciplinary collaboration to improve patient outcomes in this complex disease landscape.

Original languageEnglish
Pages (from-to)e432054
JournalAmerican Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting
Issue number3
StatePublished - May 21 2024


  • Humans
  • Urinary Bladder Neoplasms/drug therapy
  • Disease Management
  • Antineoplastic Combined Chemotherapy Protocols/therapeutic use
  • Carcinoma, Transitional Cell/drug therapy
  • Combined Modality Therapy


Dive into the research topics of 'Advancements in Urothelial Cancer Care: Optimizing Treatment for Your Patient'. Together they form a unique fingerprint.

Cite this